Hikal Ltd

- Q1 FY26 CAPEX was Rs. 31 crores focused on debottlenecking, regulatory upgrades, and CDMO capacity augmentation. - Full-year CAPEX guidance remains Rs. 200 crores, with disciplined allocation towards high ROI projects aligned with long-term growth. - Ongoing facility and quality control upgrades as part of corrective measures post US FDA OAI status; includes some capital expenses. - Conversion of part of the specialty chemicals plant into Pharma and Animal Health production; refitting in progress with commercial production expected in 6-9 months. - Investments continue to enhance pilot-scale capacities and project management for CDMO clients supporting early-stage programs. - Emphasis on capital allocation towards projects supporting regulatory readiness, operational excellence, and expansion in differentiated chemistries.

- Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. Commercial production and validation of new molecules anticipated by FY '26-FY '28. - Crop Protection Business: Flattish revenue growth expected in FY '26 amid global overcapacity and pricing pressures, with seasonal volume recovery anticipated in H2 FY '26. - Animal Health Segment: Steady progress with commercial launches planned from FY '26 onwards; diversification and portfolio expansion expected to drive long-term growth. - CDMO Segment: Robust and diversified pipeline with commercial revenues expected toward end of FY '26; growth driven by China-plus-one strategy and global innovators. - Specialty Chemicals: Plant conversion and validation underway, with commercial production expected in 6-9 months, supporting future revenue growth. - Overall Outlook: Improvement expected in H2 FY '26; Q4 FY '26 anticipated as strongest quarter led by enhanced plant utilization and new product launches.

- The Pharmaceutical segment faced deferment of revenues due to the US FDA OAI status but expects recovery in Q2 and Q3 of FY '26, with no anticipated overall revenue or margin impact for the full year. - Global tariff uncertainties pose a potential risk to FY '26 guidance, but currently, Pharma is not covered by tariffs. - The company continues to invest in CAPEX (Rs. 900 crores over four years), focusing on business expansion and improvement, with expectations of better returns by FY '28. - Crop protection division expects flat revenue growth for FY '26 due to pricing pressures and oversupply but anticipates gradual volume recovery in the second half. - Operational efficiencies and cost reductions are targeted to protect margins amid pricing pressures. - New molecule commercial launches are planned mainly from the Panoli site, with dual-site options offered to customers. - CDMO and Animal Health segments are growing, with commercial launches expected from FY '26 onwards, supporting mid- to long-term earnings growth. - Overall, the company projects revenue growth of 12%-14% in Pharma with slight improvement in EBITDA margins over FY '26.

- No explicit mention of the current or expected order book value was provided on page 17. - Customers have deferred shipments due to the OAI status at the Bangalore facility; however, no orders have been canceled. - Deferred revenue is approximately Rs. 50 crores from Q1, expected to be realized in Q2 and Q3. - Customers have reaffirmed their commitment to pick up products within Q2 and Q3. - The company is confident of recovering deferred volumes by end of the second and third quarters of FY '26. - The CDMO pipeline remains robust and diversified, with multiple projects transitioning from early development to pilot scale; commercial revenues expected towards the end of FY '26. - Overall, the company sees no loss of orders, only deferments, and maintains a healthy pipeline.

- No specific mention of new fundraising through debt or equity in the provided transcript. - The company reported maintaining a stable debt-equity ratio of 0.54 as of Q1 FY26. - CAPEX for Q1 FY26 was Rs. 31 crores, with a full-year CAPEX guidance of Rs. 200 crores focused on high ROI projects. - The balance sheet and cash flow are described as strong. - The company emphasizes disciplined capital allocation toward growth, with no indication of planned equity or debt raising activities at this time.